Search

Your search keyword '"Macias R.I.R."' showing total 24 results
Start Over Author "Macias R.I.R." Publication Year Range Last 50 years
24 results on '"Macias R.I.R."'

1. Association of Adverse Perinatal Outcomes of Intrahepatic Cholestasis of Pregnancy With Biochemical Markers: Results of Aggregate and Individual Patient Data Meta-Analyses

Author

Ovadia, C., Seed, P.T., Sklavounos, A., Geenes, B., Di Ilio, C., Chambers, J., Kohari, K., Bacq, Y., Bozkurt, N., Brun-Furrer, R., Bull, L., Estiú, M.C., Grymowicz, M., Gunaydin, B., Hague, W.M., Haslinger, C., Hu, Y., Kawakita, T., Kebapcilar, A.G., Kebapcilar, L., Kondrackienė, J., Koster, M.P.H., Kowalska-Kańka, A., Kupčinskas, L., Lee, R.H., Locatelli, A., Macias, R.I.R., Marschall, H.U., Oudijk, M.A., Raz, Y., Rimon, E., Shan, D., Shao, Y., Tribe, R., Tripodi, V., Abide, C.Y., Yenidede, I., Thornton, J.G., Chappell, L.C., and Williamson, C.

Published
2020
Full Text
View/download PDF

3. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Author

Banales, J.M., Marin, J.J.G., LaMarca, A., Rodrigues, P.M., Khan, S.A., Roberts, L.R., Cardinale, V., Carpino, G., Andersen, J.B., Braconi, C., Calvisi, D.F., Perugorria, M.J., Fabris, L., Boulter, L, Macias, R.I.R., Gaudio, E., Alvaro, D., Gradilone, S.A., Strazzabosco, M, Marzioni, M., Coulouarn, C., Fouassier, L., Raggi, C., Invernizzi, P, Mertens, J.C., Moncsek, A., Rizvi, S., Heimbach, J., Groot Koerkamp, B. (Bas), Bruix, J. (J.), Forner, A., Bridgewater, J., Valle, J.W., Gores, G.J. (Gregory), Banales, J.M., Marin, J.J.G., LaMarca, A., Rodrigues, P.M., Khan, S.A., Roberts, L.R., Cardinale, V., Carpino, G., Andersen, J.B., Braconi, C., Calvisi, D.F., Perugorria, M.J., Fabris, L., Boulter, L, Macias, R.I.R., Gaudio, E., Alvaro, D., Gradilone, S.A., Strazzabosco, M, Marzioni, M., Coulouarn, C., Fouassier, L., Raggi, C., Invernizzi, P, Mertens, J.C., Moncsek, A., Rizvi, S., Heimbach, J., Groot Koerkamp, B. (Bas), Bruix, J. (J.), Forner, A., Bridgewater, J., Valle, J.W., and Gores, G.J. (Gregory)

Abstract

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.

Published
2020
Full Text
View/download PDF

6. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers

Author

Ovadia, C., Seed, P.T. (P.), Sklavounos, A., Geenes, V., Di Illio, C., Chambers, J. (John), Kohari, K., Bacq, Y., Bozkurt, N., Brun-Furrer, R., Bull, I.D. (Ian), Estiu, M.C., Grymowicz, M., Gunaydin, B., Hague, W.M., Haslinger, C., Hu, Y. (Yu), Kawakita, T., Kebapcilar, A.G., Kebapcilar, L., Kondrackiene, J. (Jurate), Koster, M.P.H., Kowalska-Kanka, A., Kupcinskas, L. (Limas), Lee, R.H., Locatelli, A. (Alberta), Macias, R.I.R., Marschall, H.-U., Oudijk, M.A. (Martijn), Raz, Y., Rimon, E., Shan, D., Shao, Y, Tribe, R., Tripodi, V., Abide, C.Y., Yenidede, I., Thornton, J.G. (Jim), Chappell, LC, Williamson, C. (Catherine), Ovadia, C., Seed, P.T. (P.), Sklavounos, A., Geenes, V., Di Illio, C., Chambers, J. (John), Kohari, K., Bacq, Y., Bozkurt, N., Brun-Furrer, R., Bull, I.D. (Ian), Estiu, M.C., Grymowicz, M., Gunaydin, B., Hague, W.M., Haslinger, C., Hu, Y. (Yu), Kawakita, T., Kebapcilar, A.G., Kebapcilar, L., Kondrackiene, J. (Jurate), Koster, M.P.H., Kowalska-Kanka, A., Kupcinskas, L. (Limas), Lee, R.H., Locatelli, A. (Alberta), Macias, R.I.R., Marschall, H.-U., Oudijk, M.A. (Martijn), Raz, Y., Rimon, E., Shan, D., Shao, Y, Tribe, R., Tripodi, V., Abide, C.Y., Yenidede, I., Thornton, J.G. (Jim), Chappell, LC, and Williamson, C. (Catherine)

Abstract

__Background__ Intrahepatic cholestasis of pregnancy is associated with adverse perinatal outcomes, but the association with the concentration of specific biochemical markers is unclear. We aimed to quantify the adverse perinatal effects of intrahepatic cholestasis of pregnancy in women with increased serum bile acid concentrations and determine whether elevated bile acid concentrations were associated with the risk of stillbirth and preterm birth. __Methods__ We did a systematic review by searching PubMed, Web of Science, and Embase databases for studies published from database inception to June 1, 2018, reporting perinatal outcomes for women with intrahepatic cholestasis of pregnancy when serum bile acid concentrations were available. Inclusion criteria were studies defining intrahepatic cholestasis of pregnancy based upon pruritus and elevated serum bile acid concentrations, with or without raised liver aminotransferase concentrations. Eligible studies were case-control, cohort, and populationbased studies, and randomised controlled trials, with at least 30 participants, and that reported bile acid concentrations and perinatal outcomes. Studies at potential higher risk of reporter bias were excluded, including case reports, studies not comprising cohorts, or successive cases seen in a unit; we also excluded studies with high risk of bias from groups selected (eg, a subgroup of babies with poor outcomes were explicitly excluded), conference abstracts, and Letters to the Editor without clear peer review. We also included unpublished data from two UK hospitals. We did a random effects meta-analysis to determine risk of adverse perinatal outcomes. Aggregate data for maternal and perinatal outcomes were extracted from case-control studies, and individual patient data (IPD) were requested from study authors for all types of study (as no control group was required for the IPD analysis) to assess associations between biochemical markers and adverse outcomes using logisti

Published
2019
Full Text
View/download PDF

8. 1051 THE MAGNITUDE OF THE RESPONSE OF HEPATOCELLULAR CARCINOMA AND CHOLANGIOCARCINOMA TO SORAFENIB IS AFFECTED BY THE EXPRESSION OF INACTIVATING VARIANTS IN THE SLC22A1 GENE

Author

Herráez, E., primary, Briz, O., additional, Lozano, E., additional, Macias, R.I.R., additional, Robledo, V.S., additional, Hernandez-Iglesias, J., additional, González-Hernandez, A., additional, Bujanda, L., additional, Banales, J., additional, and Marin, J.J.G., additional

Published
2013
Full Text
View/download PDF

9. Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy

Author

Martinez-Becerra, P., primary, Monte, I., additional, Romero, M.R., additional, Serrano, M.A., additional, Vaquero, J., additional, Macias, R.I.R., additional, Del Rio, A., additional, Grañé-Boladeras, N., additional, Jimenez, F., additional, San-Martin, F. Gonzalez, additional, Pastor-Anglada, M., additional, and Marin, J.J.G., additional

Published
2012
Full Text
View/download PDF

20. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma

Author

Macias, R.I.R. (Rocío I. R.)

Subjects
Biliary cancer, Differential diagnosis, Metabolites, Pancreatic cancer, Tumor non-invasive biomarker
Abstract

The diagnosis of adenocarcinomas located in the pancreas head, i.e., distal cholangiocarcinoma (dCCA) and pancreatic ductal adenocarcinoma (PDAC), constitutes a clinical challenge because they share many symptoms, are not easily distinguishable using imaging techniques and accurate biomarkers are not available. Searching for biomarkers with potential usefulness in the differential diagnosis of these tumors, we have determined serum metabolomic profiles in healthy controls and patients with dCCA, PDAC or benign pancreatic diseases (BPD). Ultra-high-performance liquid chromatography coupled to mass spectrometry (UHPLC-MS) analysis was performed in serum samples from dCCA (n = 34), PDAC (n = 38), BPD (n = 42) and control (n = 25) individuals, divided into discovery and validation cohorts. This approach permitted 484 metabolites to be determined, mainly lipids and amino acids. The analysis of the results led to the proposal of a logistic regression model able to discriminate patients with dCCA and PDAC (AUC value of 0.888) based on the combination of serum levels of nine metabolites (acylcarnitine AC(16:0), ceramide Cer(d18:1/24:0), phosphatidylcholines PC(20:0/0:0) and PC(O-16:0/20:3), lysophosphatidylcholines PC(20:0/0:0) and PC(0:0/20:0), lysophosphatidylethanolamine PE(P-18:2/0:0), and sphingomyelins SM(d18:2/22:0) and SM(d18:2/23:0)) and CA 19-9. In conclusion, we propose a novel specific panel of serum metabolites that can help in the differential diagnosis of dCCA and PDAC. Further validation of their clinical usefulness in prospective studies is required.

Published
2020

21. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis

Author

Agata Majewska, Jessica A Marathe, Jenny Chambers, Romana Brun-Furrer, Ugo Indraccolo, Yue Cui, Stefan C. Kane, George Attilakos, Maria C. Estiú, L.F. Audris Wong, Andrew Shennan, Rachel M. Tribe, Michael J. Peek, Richard H. Lee, Keren Zloto, Jim G Thornton, Hanns-Ulrich Marschall, Tharni Vasavan, Yoav Yinon, Yannick Bacq, Caroline Ovadia, Berrin Günaydin, Xiaohua Liu, Yayi Hu, Catherine Williamson, Jūratė Kondrackienė, Ayse Gul Kebapcilar, Martijn A. Oudijk, Qianwen Zhang, Kasia Maksym, Victoria Geenes, William M. Hague, Alexander Juusela, Min Ding, Levent Kebapcilar, Valeria Tripodi, Deniz Oztekin, Kajol Patel, Rocio I.R. Macias, Nicholas A. Williamson, Christian Haslinger, Monika Grymowicz, Linoy Batsry, Fergus W. Gardiner, Naciye Turk Ozterlemez, Riza Madazli, Lucy C Chappell, Peter H. Dixon, Paul T. Seed, Anna Locatelli, Kelsey Broom, Maria P.H. Koster, Laura N. Bull, Jenna Sajous, Adam Morton, Francesco Azzaroli, Katherine Kohari, Ovadia C., Sajous J., Seed P.T., Patel K., Williamson N.J., Attilakos G., Azzaroli F., Bacq Y., Batsry L., Broom K., Brun-Furrer R., Bull L., Chambers J., Cui Y., Ding M., Dixon P.H., Estiu M.C., Gardiner F.W., Geenes V., Grymowicz M., Gunaydin B., Hague W.M., Haslinger C., Hu Y., Indraccolo U., Juusela A., Kane S.C., Kebapcilar A., Kebapcilar L., Kohari K., Kondrackiene J., Koster M.P.H., Lee R.H., Liu X., Locatelli A., Macias R.I.R., Madazli R., Majewska A., Maksym K., Marathe J.A., Morton A., Oudijk M.A., Oztekin D., Peek M.J., Shennan A.H., Tribe R.M., Tripodi V., Turk Ozterlemez N., Vasavan T., Wong L.F.A., Yinon Y., Zhang Q., Zloto K., Marschall H.-U., Thornton J., Chappell L.C., Williamson C., Obstetrics and Gynaecology, ARD - Amsterdam Reproduction and Development, Ovadia, C, Sajous, J, Seed, P, Patel, K, Williamson, N, Attilakos, G, Azzaroli, F, Bacq, Y, Batsry, L, Broom, K, Brun-Furrer, R, Bull, L, Chambers, J, Cui, Y, Ding, M, Dixon, P, Estiu, M, Gardiner, F, Geenes, V, Grymowicz, M, Gunaydin, B, Hague, W, Haslinger, C, Hu, Y, Indraccolo, U, Juusela, A, Kane, S, Kebapcilar, A, Kebapcilar, L, Kohari, K, Kondrackiene, J, Koster, M, Lee, R, Liu, X, Locatelli, A, Macias, R, Madazli, R, Majewska, A, Maksym, K, Marathe, J, Morton, A, Oudijk, M, Oztekin, D, Peek, M, Shennan, A, Tribe, R, Tripodi, V, Turk Ozterlemez, N, Vasavan, T, Wong, L, Yinon, Y, Zhang, Q, Zloto, K, Marschall, H, Thornton, J, Chappell, L, Williamson, C, Obstetrics & Gynecology, and Amsterdam Reproduction & Development (AR&D)

Subjects
Cholagogues and Choleretics, medicine.medical_specialty, medicine.drug_class, Cholestasis, Intrahepatic, 03 medical and health sciences, 0302 clinical medicine, Cholestasis, Pregnancy, Internal medicine, Cholestasis of pregnancy, Humans, Medicine, Hepatology, Bile acid, business.industry, Obstetrics, Individual participant data, Gastroenterology, Obstetrics and Gynecology, General Medicine, Odds ratio, medicine.disease, Ursodeoxycholic acid, Pregnancy Complications, 030220 oncology & carcinogenesis, Meta-analysis, Female, 030211 gastroenterology & hepatology, stillbirth, Ursodeoxycholic acid, pregnancy, intrahepatic cholestasis of pregnancy, business, medicine.drug, Cohort study
Abstract

Background: Ursodeoxycholic acid is commonly used to treat intrahepatic cholestasis of pregnancy, yet its largest trial detected minimal benefit for a composite outcome (stillbirth, preterm birth, and neonatal unit admission). We aimed to examine whether ursodeoxycholic acid affects specific adverse perinatal outcomes. Methods: In this systematic review and individual participant data meta-analysis, we searched PubMed, Web of Science, Embase, MEDLINE, CINAHL, Global Health, MIDIRS, and Cochrane without language restrictions for relevant articles published between database inception, and Jan 1, 2020, using search terms referencing intrahepatic cholestasis of pregnancy, ursodeoxycholic acid, and perinatal outcomes. Eligible studies had 30 or more study participants and reported on at least one individual with intrahepatic cholestasis of pregnancy and bile acid concentrations of 40 μmol/L or more. We also included two unpublished cohort studies. Individual participant data were collected from the authors of selected studies. The primary outcome was the prevalence of stillbirth, for which we anticipated there would be insufficient data to achieve statistical power. Therefore, we included a composite of stillbirth and preterm birth as a main secondary outcome. A mixed-effects meta-analysis was done using multi-level modelling and adjusting for bile acid concentration, parity, and multifetal pregnancy. Individual participant data analyses were done for all studies and in different subgroups, which were produced by limiting analyses to randomised controlled trials only, singleton pregnancies only, or two-arm studies only. This study is registered with PROSPERO, CRD42019131495. Findings: The authors of the 85 studies fulfilling our inclusion criteria were contacted. Individual participant data from 6974 women in 34 studies were included in the meta-analysis, of whom 4726 (67·8%) took ursodeoxycholic acid. Stillbirth occurred in 35 (0·7%) of 5097 fetuses among women with intrahepatic cholestasis of pregnancy treated with ursodeoxycholic acid and in 12 (0·6%) of 2038 fetuses among women with intrahepatic cholestasis of pregnancy not treated with ursodeoxycholic acid (adjusted odds ratio [aOR] 1·04, 95% CI 0·35–3·07; p=0·95). Ursodeoxycholic acid treatment also had no effect on the prevalence of stillbirth when considering only randomised controlled trials (aOR 0·29, 95% CI 0·04–2·42; p=0·25). Ursodeoxycholic acid treatment had no effect on the prevalence of the composite outcome in all studies (aOR 1·28, 95% CI 0·86–1·91; p=0·22), but was associated with a reduced composite outcome when considering only randomised controlled trials (0·60, 0·39–0·91; p=0·016). Interpretation: Ursodeoxycholic acid treatment had no significant effect on the prevalence of stillbirth in women with intrahepatic cholestasis of pregnancy, but our analysis was probably limited by the low overall event rate. However, when considering only randomised controlled trials, ursodeoxycholic acid was associated with a reduction in stillbirth in combination with preterm birth, providing evidence for the clinical benefit of antenatal ursodeoxycholic acid treatment. Funding: Tommy's, the Wellcome Trust, ICP Support, and the National Institute for Health Research.

Published
2021

22. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

Author

Giovanni Brandi, Giulia Mentrasti, Vincenzo Cardinale, Jose J.G. Marin, Maite G. Fernandez-Barrena, John Bridgewater, Oreste Segatto, Angela Lamarca, Rocio I.R. Macias, Arndt Vogel, Jesus M. Banales, Patricia Munoz-Garrido, Pilar Acedo, Ana Landa-Magdalena, Cecília M. P. Rodrigues, Juan W. Valle, Marco Marzioni, Chiara Braconi, Adelaida La Casta, Pedro M. Rodrigues, Simona Tavolari, Joachim C. Mertens, Ana Da Silva Ruivo, Maria Giuseppina Prete, Marin J.J.G., Prete M.G., Lamarca A., Tavolari S., Landa-Magdalena A., Brandi G., Segatto O., Vogel A., Macias R.I.R., Rodrigues P.M., Casta A.L., Mertens J., Rodrigues C.M.P., Fernandez-Barrena M.G., Da Silva Ruivo A., Marzioni M., Mentrasti G., Acedo P., Munoz-Garrido P., Cardinale V., Banales J.M., Valle J.W., Bridgewater J., and Braconi C.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Review Article, biliary tract cancer, chemotherapy, Systemic therapy, Cholangiocarcinoma, 03 medical and health sciences, 0302 clinical medicine, Stroma, Internal medicine, Tumor Microenvironment, Medicine, Humans, Molecular Targeted Therapy, Precision Medicine, Chemotherapy, Clinical Trials as Topic, Molecular medicine, business.industry, Liquid Biopsy, Correction, Biliary cancer, Phenotype, 3. Good health, Strategies for treating patients, Biliary Tract Neoplasms, Liver, Biliary tract, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Molecular targets, Biliary tract cancer, Immunotherapy, business, Biliary tract cancers (BTCs), Adjuvant, Aggressive malignancies
Abstract

Biliary tract cancers (BTCs) are a group of rare and aggressive malignancies that arise in the biliary tree within and outside the liver. Beyond surgical resection, which is beneficial for only a small proportion of patients, current strategies for treating patients with BTCs include chemotherapy, as a single agent or combination regimens, in the adjuvant and palliative setting. Increased characterisation of the molecular landscape of these tumours has facilitated the identification of molecular vulnerabilities, such as IDH mutations and FGFR fusions, that can be exploited for the treatment of BTC patients. Beyond targeted therapies, active research avenues explore the development of novel therapeutics that target the crosstalk between cancer and stroma, the cellular pathways involved in the regulation of cell death, the chemoresistance phenotype and the dysregulation of RNA. In this review, we discuss the therapeutic opportunities currently available in the management of BTC patients, and explore the strategies that can support the implementation of precision oncology in BTCs, including novel molecular targets, liquid biopsies and patient-derived predictive tools.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results